Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.

  title={Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.},
  author={Bernd Richter and Elizabeth Bandeira-Echtler and Karla Bergerhoff and Christian Lerch},
  journal={The Cochrane database of systematic reviews},
BACKGROUND In type 2 diabetes mellitus there is a progressive loss of beta-cell function. One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors like sitagliptin and vildagliptin. OBJECTIVES To assess the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. SEARCH STRATEGY Studies were obtained from computerised searches of MEDLINE, EMBASE and The Cochrane Library. SELECTION CRITERIA Studies were… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 122 extracted citations

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

Diabetes, metabolic syndrome and obesity : targets and therapy • 2009
View 5 Excerpts
Highly Influenced

Switching from Premixed Insulin To Basal Insulin Analogue For Type 2 Diabetes and Role of Dipeptidyl Peptidase-4 Inhibitors.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association • 2018
View 2 Excerpts


Publications referenced by this paper.
Showing 1-10 of 23 references

Meglitinide analogues for type 2 diabetes mellitus.

The Cochrane database of systematic reviews • 2007

DPP-4 inhibitors and their potential role in the management of type 2 diabetes.

International journal of clinical practice • 2006
View 3 Excerpts

Similar Papers

Loading similar papers…